CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...

Clearmind Medicine (CMND) has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of ...